Please assess the completion status of the following clinical trial:

Trial Title: Surgical Treatment of Peri-implantitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Presence of ≥ 1 implant with a probing depth (PD) ≥ 5 mm with bleeding and/or suppuration (SUP) on probing, and peri-implant bone loss ≥ 3mm with an intraosseous defect component~Exclusion Criteria:~* Smokers \> 10 cigarettes per day~* Patients with uncontrolled diabetes mellitus~* Pregnant or lactating women (self reported)~* Patients with a systemic illness that preclude them from oral surgery~* Patients with an allergy to amoxicillin or metronidazole or chlorhexidine.~* Patients requiring antibiotic prophylaxis and Patients who have taken antibiotics in the past 3 months

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Control Group 1 (Type: ACTIVE_COMPARATOR): Access flap, implant surface decontamination (saline), systemic antibiotics (amoxicillin 500 mg and metronidazole 400 g, 3 x day for 7 days)
- Test Group 2 (Type: ACTIVE_COMPARATOR): Access flap, implant surface debridement, systemic antibiotics (amoxicillin 500 mg, metronidazole 400 g, 3 x day for 7 days), bovine bone substitute material (BioOss®) and collagen membrane (BioGide®)

Based on this trial design, predict the completion outcome and termination type (if applicable).